Synaffix Announces Expansion of Mersana License Deal to a Total Potential Value Exceeding $1 Billion
- Expanded deal focuses on Synaffix’s GlycoConnect™ site-specific ADC bioconjugation technology and adds license options for six new programs to existing deal
- Mersana currently developing two programs based on GlycoConnect™ site-specific ADC bioconjugation technology (XMT-1592 and XMT-1660)
AMSTERDAM, NETHERLANDS, November 30, 2021 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces the expansion of its license agreement with Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need.
